Replimune falls after FDA's Makary defends decision on cancer drug
FDA Commissioner Makary defends agency's decision on Replimune's drug
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
NASDAQ RESUMED AT 11:15 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:52 AM
Street View: Tough path ahead for Replimune after second FDA setback on melanoma drug
Replimune slumps after FDA drug rejection prompts downgrades
U.S. RESEARCH ROUNDUP-Chevron, Ford, Occidental Petroleum
NASDAQ RESUMED AT 07:50 PM
Replimune tumbles after FDA declines to approve melanoma drug
Brief: Replimune Group Disagrees With FDA About Whether Rp1 BLA Data Set Is Enough To Allow The Medicine To Be Made Available To Advanced Cancer Patients
Brief: FDA Says Data Insufficient To Conclude Effectiveness Of Replimune's vusolimogene oderparepvec
US FDA declines to approve Replimune's drug for advanced skin cancer (updated)
US FDA declines to approve Replimune's drug for advanced skin cancer
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:53 AM
Replimune's Q3 net loss widens as R&D expenses rise
Brief: Replimune Group Q3 Net Income USD -70.93 Million